

this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

(a) Please amend claims 15, 20, 22, 23 and 26-28 as follows:

(Please substitute the following claim 15 in place of pending claim 15:)

10³

C1 ✓ 15. (Twice amended) A tumor vaccine based on tumor antigens comprising (a) a tumor antigen source and (b) an interferon-gamma (IFN-γ) release system that is separate from said tumor antigen source, wherein said IFN-γ release system releases an effective dose of IFN-γ within a period of time ranging from 30 minutes to 8 days, said effective dose of IFN-γ ranging from 50 ng to 5 μg.

(Please substitute the following claim 20 in place of pending claim 20:)

10³

C2 ✓ 20. (Once amended) The tumor vaccine of claim 15, wherein said IFN-γ release system comprises liposomes containing IFN-γ.

(Please substitute the following claim 22 in place of pending claim 22:)

C3 ✓ 22. (Once amended) The tumor vaccine of claim 15, wherein said IFN-γ release system comprises microspheres containing IFN-γ.

{ Please substitute the following claim 23 in place of pending claim 23: }

C3 103 23. (Once amended) The tumor vaccine of claim 15, wherein said IFN- γ release system comprises [minipellets] containing IFN- γ .

{ Please substitute the following claim 26 in place of pending claim 26: }

103 26. (Once amended) The tumor vaccine of claim 24, wherein the tumor cells comprise peptides derived from tumor antigens, and wherein said peptides induce an immune response in an individual into whom said tumor cells are introduced.

{ Please substitute the following claim 27 in place of pending claim 27: }

C4 27. (Once amended) The tumor vaccine of claim 15, wherein the tumor antigen source consists of antigen-presenting cells which comprise tumor antigen peptides, and wherein said peptides induce an immune response in an individual into whom said antigen-presenting cells are introduced.

C4 103 { Please substitute the following claim 28 in place of pending claim 28: }

28. (Once amended) The tumor vaccine of claim 15, wherein the tumor antigen source comprises tumor antigens or peptides derived therefrom.

{ (b) Please enter the following new claims 29-38: }

103 C5 29. (New) The tumor vaccine of claim 15, further comprising at least one cytokine selected from the group consisting of interleukin-2 (IL-2), IL-4, IL-12, IFN- α , IFN- β , IFN- ω and tumor necrosis factor-alpha (TNF- α).

103 30. (New) The tumor vaccine of claim 29, wherein said at least one cytokine is contained in the IFN- γ release system.

103 31. (New) The tumor vaccine of claim 29, wherein said at least one cytokine is contained in a second release system distinct from the IFN- γ release system.

103 32. (New) The tumor vaccine of claim 31, wherein said second release system comprises liposomes containing said at least one cytokine.

103 33. (New) The tumor vaccine of claim 31, wherein said second release system comprises microspheres containing said at least one cytokine.

C5
103 34. (New) The tumor vaccine of claim 31, wherein said second release system comprises minipellets containing said at least one cytokine.

amb
103 35. (New) The tumor vaccine of claim 31, wherein said second release system comprises tumor cells transfected with a gene encoding said at least one cytokine.

103 36. (New) The tumor vaccine of claim 35, wherein said transfected tumor cells also function as said tumor antigen source.

103 37. (New) The tumor vaccine of claim 15, further comprising a non-specific immunostimulant adjuvant.

CS
M

38. (New) The tumor vaccine of claim 29, further comprising a non-specific immunostimulant adjuvant.
